• Winter Storm Watch - Click for Details
    ...WINTER STORM WATCH IN EFFECT FROM WEDNESDAY MORNING THROUGH LATE WEDNESDAY NIGHT...
    Effective: February 12, 2025 @ 6:00am
    Expires: February 13, 2025 @ 3:00am
    WHAT
    Heavy snow possible. Total snow accumulations between 6 and 8 inches possible.
    WHERE
    Portions of north central, northwest, and west central Illinois and east central, northeast, and southeast Iowa.
    WHEN
    From Wednesday morning through late Wednesday night.
    IMPACTS
    Travel could be very difficult. The hazardous conditions could impact the Wednesday morning and evening commutes.
    ADDITIONAL DETAILS
    North winds 10 to 15 mph, with gusts up 25 mph may cause some blowing and drifting snow, especially on east-west roads.
    PRECAUTIONARY/PREPAREDNESS ACTIONS
    Monitor the latest forecasts for updates on this situation.

Bayer pharma chief sees no big acquisitions in near future

SHARE NOW

ZURICH (Reuters) – Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the German company’s pharmaceuticals division said in an interview published on Tuesday.

“I don’t see any major acquisitions in the next two or three years at least,” Stefan Oelrich told Swiss newspaper Neue Zuercher Zeitung.

Over the last five or six years, the pharmaceutical division has invested between 8 billion and 10 billion euros($8.20 billion and $10.25 billion) in external deals, he said, with the group’s priority now to reduce debt.

“But we have a small acquisition budget, for example for the purchase of additional licenses,” he told the newspaper.

Oelrich said there was also no reason to split Bayer, whose businesses span agrochemicals, pharmaceuticals and non-prescription drugs.

“We function with three very independent businesses,” he said. “As long as the structure does not hinder the individual businesses in our respective markets, there is no reason to break it up,” he told the newspaper.

“We may no longer be among the top five in the world in the pharmaceutical business, but in this business, size is not the decisive factor. Innovation is.”

($1 = 0.9757 euros)

(Reporting by John Revill, editing by Rachel More)

Brought to you by www.srnnews.com

Submit a Comment